|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Gilead Sciences has expanded beyond its leading antiviral drug franchises for the treatment of HIV and hepatitis C with the announced acquisition of Kite Pharmaceuticals, giving Gilead a leading edge in cell therapy technology in oncology.
Juno Therapeutics Inc (NASDAQ:JUNO) has a lot going for it off and on the price chart. That doesn’t mean you shouldn’t immunize JUNO stock against the always-real bearish threats. To do that, we’ll explore a fully-hedged, collar-based therapy program. Let me explain.
Alnylam (ALNY) and partner Sanofi RNAi therapeutic patisiran met its primary efficacy endpoint and all secondary endpoints in the phase III APOLLO study.